These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 27249733)

  • 1. Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer.
    Hashemi-Sadraei N; Sikora AG; Brizel DM
    Am Soc Clin Oncol Educ Book; 2016; 35():e277-82. PubMed ID: 27249733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.
    Moy JD; Moskovitz JM; Ferris RL
    Eur J Cancer; 2017 May; 76():152-166. PubMed ID: 28324750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manipulating the Immune System With Checkpoint Inhibitors for Patients With Metastatic Sarcoma.
    D'Angelo SP
    Am Soc Clin Oncol Educ Book; 2016; 35():e558-64. PubMed ID: 27249767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Not Available].
    Reverdy T; Gau M; Karabajakian A; Neidhardt EM; Fayette J
    Bull Cancer; 2018 Dec; 105 Suppl 1():S35-S42. PubMed ID: 30595197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab in recurrent/metastatic head and neck cancers.
    Karabajakian A; Reverdy T; Gau M; Fayette J
    Future Oncol; 2018 Mar; 14(7):603-609. PubMed ID: 29130342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the clinical development of immune checkpoint blockade therapy.
    Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
    Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers.
    Economopoulou P; Kotsantis I; Psyrri A
    Curr Treat Options Oncol; 2016 Aug; 17(8):40. PubMed ID: 27315066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer—review of current data.
    Swanson MS; Sinha UK
    Oral Oncol; 2015 Jan; 51(1):12-5. PubMed ID: 25459157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in head and neck cancer: evidence and perspectives.
    Tosoni A; Franceschi E; Pasquini E; Lanese A; Donini E; Foschini MP; Dall'Olio D; Brandes AA
    Immunotherapy; 2017 Dec; 9(16):1351-1358. PubMed ID: 29185392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
    Saada-Bouzid E; Peyrade F; Guigay J
    Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Not Available].
    Thibault C
    Bull Cancer; 2018 Dec; 105 Suppl 1():S43-S49. PubMed ID: 30595198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
    Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
    Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.
    Bose CK
    Med Oncol; 2022 Jan; 39(4):47. PubMed ID: 35092506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress of immune checkpoint therapy in the clinic (Review).
    Fan Y; Zhang C; Jin S; Gao Z; Cao J; Wang A; Li D; Wang Q; Sun X; Bai D
    Oncol Rep; 2019 Jan; 41(1):3-14. PubMed ID: 30365127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
    Hu ZI; Ho AY; McArthur HL
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Advances in immune checkpoint inhibitors in gastrointestinal cancer].
    Zhu XR; Zheng LZ
    Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):646-649. PubMed ID: 28926891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The benefits of immunotherapy combinations.
    Schmidt C
    Nature; 2017 Dec; 552(7685):S67-S69. PubMed ID: 29293245
    [No Abstract]   [Full Text] [Related]  

  • 19. Checkpoint immunotherapy in head and neck cancers.
    Zolkind P; Uppaluri R
    Cancer Metastasis Rev; 2017 Sep; 36(3):475-489. PubMed ID: 28836124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.
    Flynn MJ; Larkin JMG
    Expert Opin Pharmacother; 2017 Oct; 18(14):1477-1490. PubMed ID: 28820000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.